Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: : The present study was performed to investigate the validity and reliability of the Korean version of the THINC-it tool (THINC-it-K) in adult patients with major depressive disorder (MDD).
Methods: : Subjects aged 19-65 years with recurrent MDD experiencing moderate to severe major depressive episode (n = 44) were evaluated and compared to age and sex matched healthy controls (n = 44). Subjects completed the THINC-it-K which includes variants of the Identification Task (IDN) using Choice Reaction Time, One-Back Test, Digit Symbol Substitution Test, Trail Making Test-Part B, and the Perceived Deficits Questionnaire for Depression-5-item (PDQ-5-D).
Results: : A total of 75.0% of patients with MDD exhibited cognitive performance 1 standard deviation or below. The differences in Spotter ( = 0.001), Codebreaker ( = 0.001), PDQ-5-D ( ＜ 0.001) and objective THINC-it-K composite score ( = 0.002) were significant between the two groups. Concurrent validity of the THINC-it-K based on a calculated composite score was good (r = 0.856, ＜ 0.001), and ranges for each component tests were from 0.076 (IDN) to 0.928 (PDQ-5-D).
Conclusion: : The THINC-it-K exhibits good reliability and validity in adults with MDD. It could be a useful tool for the measurement of cognitive deficits in persons with MDD and should be implemented in clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11289603 | PMC |
| http://dx.doi.org/10.9758/cpn.23.1135 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Impact of transcranial magnetic stimulation on depressive symptoms relief in patients with chronic neuropathic pain and comorbid depression: A narrative literature review].
Encephale
September 2025
Centre de référence régional des pathologies anxieuses et de la dépression, pôle de psychiatrie générale et universitaire, centre hospitalier Charles-Perrens, 33076 Bordeaux, France; Inserm U1215, Neurocentre Magendie, 33000 Bordeaux, France. Electronic address:
Neuropathic pain results from an injury or a dysfunction of the somatosensory system. Management of this disease is complex due to a restricted therapeutic arsenal and limited efficacy of currently available treatments. Because of its chronic and disabling nature, neuropathic pain is strongly associated with depressive disorders.
View Article and Find Full Text PDFKetamine and Esketamine for Late-Life Depression: A Systematic Review of Efficacy, Safety, and Tolerability.
Am J Geriatr Psychiatry
August 2025
Mood Disorder and Psychopharmacology Unit (RS, JKT, CED, RSM), University Health Network, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronnto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, ON, Canada. Electronic address: roger.mcintyre@
Ketamine has emerged as a promising treatment for major depression, though its efficacy and safety remain incompletely characterized in older adults. This systematic review synthesizes current evidence for ketamine in geriatric depression. A search of PubMed, EMBASE, and PsycINFO was conducted.
View Article and Find Full Text PDFIs the Time Right to Start Testing if Late-Onset Depression is Associated With the Development of an α-Synucleinopathy Like Parkinson's Disease? A Double Systematic Review and Meta-Analysis.
Am J Geriatr Psychiatry
August 2025
Department of Psychiatry (MLO, SEC, JZ, KS), Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands; Neuroimmunology Research Group (KS), Netherlands Institute for Neuroscience, Amsterdam, The Netherlands; Psychiatric Program of the Netherlands Brain Bank (KS), Ne
Parkinson's disease (PD) is characterized by two neurobiological markers: pathological α-synuclein and/or a dopaminergic deficit. Depression is common in PD, and may precede motor signs, particularly in late-onset depression (LOD). We conducted two systematic reviews and a meta-analysis to examine the relationship between depression and PD development.
View Article and Find Full Text PDFDeveloping Clinically Interpretable Neuroimaging Biotypes in Psychiatry.
Biol Psychiatry
September 2025
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA; Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, 94304, USA. Electronic address: leawillia
Despite available treatments, major depressive disorder (MDD) remains one of the leading causes of disability across medical conditions. The current symptom-based diagnostic system groups patients with highly heterogeneous presentations, with no biomarkers to guide treatment-akin to diagnosing heart disease solely by chest pain, without imaging to reveal the underlying pathology. Lacking biological guidance, clinicians rely on trial-and-error prescribing.
View Article and Find Full Text PDFBlood transcriptomic analysis reveals a distinct molecular subtype of treatment resistant depression compared to non-treatment resistant depression.
Brain Behav Immun
September 2025
Centre for Genomic Regulation (CRG), The Barcelona Institute for Science and Technology (BIST), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; Biomedical Research Networking Center for Rare Diseases (CIBERER), Barcelona 08003, Spain.
Treatment-resistant depression (TRD) is a severe condition characterized by chronic and recurrent depressive symptoms, leading to significant morbidity and a considerable socio-economic impact. Genetic and biological studies suggest that TRD is associated with distinct biological characteristics. In this study, we analysed whole-transcriptome differences in 293 patients with major depressive disorder (MDD) to compare TRD (N = 150) vs non-TRD (N = 143) cases.
View Article and Find Full Text PDF